CND

Kane Biotech Announces First Quarter 2024 Financial Results

Retrieved on: 
목요일, 5월 23, 2024
Patent, Income tax, FDA, Sale, CND, Financial statement, Transaction, KNE, TSX Venture Exchange

WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results.

Key Points: 
  • WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results.
  • Gross profit for the first quarter of 2024 was $560,786, an increase of 63% compared to $345,047 for the first quarter of 2023.
  • Detailed financial information about Kane Biotech can be found in its March 31, 2024 Financial Statements and Management Discussion and Analysis on SEDAR and the Company’s website.
  • Detailed financial information about Kane Biotech can be found in its March 31, 2024 Financial Statements and Management Discussion and Analysis on SEDAR and the Company’s website.

Kane Biotech to Host Investor Webinar

Retrieved on: 
화요일, 4월 16, 2024
Acne, Sale, CND, KNE

WINNIPEG, Manitoba, April 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time.

Key Points: 
  • WINNIPEG, Manitoba, April 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time.
  • Marc Edwards, Kane's President & CEO, will share his thoughts on what the sale of STEM Animal Health, which should ultimately net Kane more than $13 million CND, means for Kane as an important step in becoming a market leader in the growing high-value wound care and dermatological markets.
  • The transaction, which focuses the company and significantly improves the balance sheet, will provide the necessary capital to achieve key milestones such as commercial launches and global growth, as well as our clinical programs in both wound care and acne.

Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products

Retrieved on: 
월요일, 4월 15, 2024
Sale, Non, CND, Partnership, Transaction, KNE, TSX Venture Exchange, Growth, Bank

Overall, it is anticipated that the sale of STEM will net Kane an estimated CND $11,500,000.

Key Points: 
  • Overall, it is anticipated that the sale of STEM will net Kane an estimated CND $11,500,000.
  • The Transaction was completed by way of a share purchase agreement between Kane, STEM, Ecuphar NV and Dechra dated April 12, 2024.
  • In connection with the Transaction, Kane also entered into a product development agreement, and a transitional manufacturing agreement with STEM.
  • In connection with the completion of the Transaction, Kane obtained the written consent of shareholders of Kane holding more than 50% of the common shares of Kane.

Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health

Retrieved on: 
목요일, 4월 11, 2024
Sale, CND, Health, Transaction, Biotechnology, KNE, TSX Venture Exchange, Interest

Overall, it is anticipated that the sale of STEM Animal Health will net Kane Biotech in excess of CND $11,500,000 (including the cash deposits already received, as noted below).

Key Points: 
  • Overall, it is anticipated that the sale of STEM Animal Health will net Kane Biotech in excess of CND $11,500,000 (including the cash deposits already received, as noted below).
  • The Purchaser is not a Non-Arm’s Length Party (as that term is defined by the TSX Venture Exchange) of the Company.
  • “We are pleased with the outcome of this transaction,” said Marc Edwards, President & CEO of Kane Biotech.
  • “Kane Biotech will be receiving full value for the successful animal health business that it created allowing the Company to significantly strengthen its balance sheet and narrow its focus on human health biofilm solutions.”
    Prior to the completion of the Transaction, the Company owned a 2/3 interest in STEM.

CND Life Sciences to Highlight Momentum of Skin Biopsy Diagnostic Tool for Parkinson’s Disease and Related Disorders at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
금요일, 4월 12, 2024
Medical Devices, Other Health, Health, Science, Research, Neurodegenerative disease, PAF, American Academy, Lewy body, MCI, CND, DLB, NIH, Skin, Autonomic nervous system, Abstract, MD, Artificial intelligence, Colorado Convention Center, Dementia, Tremor, Patient, AAN, Orthostatic hypotension, Neurology, Harvard Medical School, Diagnosis, Emerging, Biomarker, Algorithm

The results are focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI).

Key Points: 
  • The results are focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI).
  • A second abstract being presented describes the utility of the synuclein skin biopsy in the initial diagnosis and evaluation of Parkinsonian disorders in everyday clinical practice.
  • “All of the research that will be presented during AAN supports the groundbreaking diagnostic advances using skin biopsies to detect, quantify, and monitor neurodegenerative disease progression.
  • Details on relevant presentations are as follows:
    Essential Tremor with Parkinsonism with Normal Dopamine Transporter Imaging: Majority Have Evidence of Peripheral Synucleinopathy

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

Retrieved on: 
수요일, 3월 20, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, JAMA, Lewy body, Diagnosis, Harvard Medical School, American Medical Association, DLB, MSA, Disease, PD, Multiple system atrophy, Alpha-synuclein, Physician, Journal, CND, MD, NIH, Synucleinopathy, Skin, Pathology, Bangladesh Technical Education Board, Medicare, PAF, Dementia, Phosphorylation, Medical imaging

The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.

Key Points: 
  • The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.
  • The proportion of patients with P-SYN was 92.7% in those with PD, 98.2% in those with MSA, 96.0% in those with DLB, and 100% in those with PAF.
  • Future disease-modifying therapies will require convenient, accurate, and precise diagnostic tools to reach the right patients at the right time across a wide array of communities.
  • “The publication of this important NIH-sponsored study is one big step forward with many more milestones to come.”

CADCA Advocates for Community-Based Prevention at the 67th Annual United Nations Commission on Narcotic Drugs Session

Retrieved on: 
목요일, 3월 14, 2024
Narcotic, CND, Non-governmental organization

ALEXANDRIA, Va., March 14, 2024 /PRNewswire/ -- In a resolute commitment to combating substance misuse and fostering community well-being, CADCA proudly announces its active participation in the 67th Annual United Nations Commission on Narcotic Drugs (CND), taking place March 14 – 22, 2024, in Vienna, Austria. As a leading advocate for community-based prevention efforts, CADCA brings over 25 years of experience in empowering coalitions to create positive change and build a world of safer, healthier, and stronger communities.

Key Points: 
  • ALEXANDRIA, Va., March 14, 2024 /PRNewswire/ -- In a resolute commitment to combating substance misuse and fostering community well-being, CADCA proudly announces its active participation in the 67th Annual United Nations Commission on Narcotic Drugs (CND), taking place March 14 – 22, 2024, in Vienna, Austria.
  • As a leading advocate for community-based prevention efforts, CADCA brings over 25 years of experience in empowering coalitions to create positive change and build a world of safer, healthier, and stronger communities.
  • CADCA's active involvement at the 67th CND is instrumental, reflecting its commitment to advancing effective drug policies and promoting community well-being on an international stage.
  • Our involvement at the 67th CND underscores our dedication to advancing effective drug policies and promoting community well-being on a global scale."

CND Life Sciences Partners with Visiopharm on Novel AI-Tool to Detect and Quantify Pathological Alpha-Synuclein in Cutaneous Nerves

Retrieved on: 
화요일, 3월 5, 2024
Parkinson's disease, Marie Cassidy, Algorithm, Ariz, CND, MD, Pathology, Drug development, Alpha-synuclein, Neurology, LDT, Disease, Patient, Clinical trial, Sympathetic nervous system, Synucleinopathy, Diagnosis, Machine learning, Three-body problem, Deep learning, Lewy body, Partnership, Medical imaging

SCOTTSDALE, Ariz.., March 5, 2024 /PRNewswire/ -- CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today will unveil its NerValence pathology detection system at the AD/PD 2024 conference in Lisbon, Portugal. NerValence, developed through a strategic collaboration with precision pathology company Visiopharm, significantly enhances CND's biomarker testing services for clinical trials targeting the alpha-synuclein protein in patients with suspected Parkinson's disease, dementia with Lewy bodies, and related disorders.

Key Points: 
  • NerValence aids in the identification, tracking, and measuring the volume of alpha-synuclein in cutaneous nerves.
  • NerValence features machine learning algorithms that recognize and differentiate microscopic structures, nerves, and important disease markers that can be found in cutaneous tissue.
  • "Utilizing our novel deep learning technology to power this crucial advancement in neurodegenerative diseases represents a significant leap forward in analyzing peripheral nerves," said Michael Grunkin , Visiopharm Chief Executive Officer.
  • "Collaborating with CND Life Sciences on its deployment of NerValence will continue to be a major priority as we advance AI-driven precision pathology to enhance biopharmaceutical drug development."

SOSi Awarded Contract to Deliver Intelligence Solutions to U.S. Army Europe and Africa

Retrieved on: 
수요일, 1월 3, 2024
ISR, USAREUR, Army, CND, Intelligence, SOSI, Arms industry

RESTON, Va., Jan. 3, 2024 /PRNewswire/ -- SOSi today announced it was awarded a prime contract to provide a broad range of support services to the intelligence directorate of U.S. Army Europe and Africa (USAREUR-AF).

Key Points: 
  • Contract extends delivery of intelligence support services, ISR integration, and future threat assessments
    RESTON, Va., Jan. 3, 2024 /PRNewswire/ -- SOSi today announced it was awarded a prime contract to provide a broad range of support services to the intelligence directorate of U.S. Army Europe and Africa (USAREUR-AF).
  • SOSi will provide intelligence technical support services to the intelligence directorate of USAREUR-AF.
  • The contract includes multidiscipline intelligence analysis; intelligence, surveillance, and reconnaissance (ISR) planning and integration; intelligence planning, training, and exercise support; cyber network defense (CND) and systems engineering services.
  • For this newly awarded intelligence technical support services (ITSS) contract, more than 130 SOSi intelligence professionals, language experts, and security experts will deliver direct support to the USAREUR-AF intelligence directorate and its numerous subordinate commands in Germany, Italy, Belgium, Kosovo and Turkey.

CND Life Sciences Wins Prestigious Award as it Drives Innovation in Neurodiagnostics Field

Retrieved on: 
목요일, 11월 16, 2023
DSM-IV codes, Parkinson's disease, CND, Patient, Ecosystem, Neurology, NIH, Neurodegenerative disease, Diagnosis, Trial of the century, Pharmaceutical industry

SCOTTSDALE, Ariz., Nov. 16, 2023 /PRNewswire/ -- CND Life Sciences, a medical technology company pioneering the development of skin-based tests to help clinicians diagnose neurodegenerative diseases and other neurologic disorders, has been named a 2023 Fast Lane Honoree by the Arizona Bioindustry Association (AZBio). The award is given to a select few companies each year for achieving outstanding milestones in the previous 18 months.

Key Points: 
  • The award is given to a select few companies each year for achieving outstanding milestones in the previous 18 months.
  • "We are incredibly grateful for being honored with a 2023 AZBio Fast Lane Award," said CND Chief Medical Officer and Co-Founder, Dr. Todd Levine.
  • "For the progress it is making in building a growing Arizona medical technology company, CND Life Sciences was very deserving of the 2023 AZBio Fast Lane Award," said Joan Koerber-Walker, President and CEO of AZBio.
  • "We look forward to witnessing and supporting CND's continued innovation and impact in the field of neurodegenerative medicine."